Physician profile
Isabel Hepp
NPI 1831965227
$4,421.35
in general payments reported to CMS, 2019-2025
23 companies · $2,669 in 2025
The $2,669 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,752 · 2025: $2,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,191.58 |
| Education | $229.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.32 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $597.19 | 2024-2025 | Dupixent |
| Ucb, INC. | $534.33 | 2024-2025 | Bimzelx |
| Incyte Corporation | $340.56 | 2024-2025 | Opzelura |
| Genzyme Corporation | $339.73 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $266.06 | 2024-2025 | |
| Janssen Biotech, INC. | $246.15 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $236.02 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $197.48 | 2024-2025 | |
| Galderma Laboratories, L.P. | $169.09 | 2025 | Nemluvio |
| Lilly USA, LLC | $163.65 | 2024-2025 | Ebglyss, Taltz |
| Amgen INC. | $145.63 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $105.46 | 2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $89.53 | 2024-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $79.58 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $61.99 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $45.54 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.76 | 2025 | Cabtreo, Jublia, Siliq |
| Dermavant Sciences, INC. | $25.48 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $23.59 | 2025 | Valchlor |
| Organon LLC | $23.30 | 2025 | Vtama |
| Botanix Sb INC | $18.30 | 2025 | Sofdra |
| Journey Medical Corporation | $15.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Hepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.